VIVES is a multi-sector fund that invests in projects with a positive societal impact
Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted...
Issam Doghri, Prof. at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Gael Rouvroy, CEO intoPIX:
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to